证券代码：002626 证券简称：金达威 公告编号：2025-046 厦门金达威集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股东大会审议通过利润分配方案等情况 厦门金达威集团股份有限公司（以下简称"公司"）2024 年年度权益分派方 案已获 2025 年 4 月 30 日召开的 2024 年度股东大会审议通过，公司 2024 年年度 权益分派方案为：公司以截止 2024 年 12 月 31 日公司总股本 609,934,771 股为基 数，向全体股东每 10 股派发现金红利 4.00 元（含税），送红股 0 股（含税），不 以公积金转增股本，剩余未分配利润结转以后年度。该次股东大会决议公告刊登 于 2025 年 5 月 6 日的公司指定信息披露媒体《证券时报》《证券日报》和巨潮资 讯网。 本次权益分派方案披露至实施期间，公司股本总额未发生变化。若本次利润 分配方案实施前公司股本发生变动，则以实施分配方案股权登记日的总股本为基 数，按照分配比例不变的原则对分配总额进行调整。本次实施的分配方案与股东 大会 ...

发明名称：一种纳豆激酶固态发酵半连续生产工艺 专利号：ZL 2023 1 0115923.0 证券代码：002626 证券简称：金达威 公告编号：2025-045 厦门金达威集团股份有限公司 关于取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）及子公司内蒙古金达威 药业有限公司、金达威生物技术（江苏）有限公司，近日收到国家知识产权局颁 发的 2 件发明专利证书，具体情况如下： 一、 一种纳豆激酶固态发酵半连续生产工艺 专利申请日：2023 年 02 月 08 日 专利权人：内蒙古金达威药业有限公司 厦门金达威集团股份有限公司 金达威生物技术（江苏）有限公司 专利权期限：二十年 证书号：第 7980285 号 授权公告日：2025 年 06 月 03 日 发明名称：一种固定化生物酶及其制备方法以及虾青素单酯的合成方法 专利号：ZL 2025 1 0132862.8 专利申请日：2025 年 02 月 06 日 专利权人：内蒙古金达威药业有限公司 金达威生物技术（江苏）有限公司 厦门金达威集团股 ...

根据市场公开信息及5月22日披露的机构调研信息，知名私募量度资本近期对1家上市公司进行了调研， 相关名单如下： 1）金达威 （深圳量度资本投资管理有限公司参与公司特定对象调研） 调研纪要：公司已顺利完成辅酶Q10原料生产线1.5倍扩产改造，新增大发酵罐已陆续试车成功，目前保 持产销两旺态势；维生素受市场波动影响价格有所落；而DH产品通过技术升级和市场推广持续提升竞 争力，为后续市场拓展奠定了稳固基础；其他原料产品如虾青素、维生素K2也有明显向好趋势。受益 于国内健康消费行业快速发展，公司保健食品成品业务国内市场拓展情况良好。公司目前没有麦角硫因 原料产品，旗下美国保健品品牌Doctor'sBest多特倍斯推出麦角硫因产品并通过跨境电商平台在国内市 场销售。目前公司辅酶Q10、维生素、维生素D3及维生素K2出口至美国市场适用的关税税率为20%。公 司已通过提高美国市场辅酶Q10原料产品的销售价格或由下游客户负担关税来抵消关税影响；维生素产 品在美国的销售占比很小，影响有限。公司将根据保健品的行业特性、市场需求以及自身的品牌定位及 资源整合能力，通过市场洞察与机会挖掘，制定产品策略、资源整合与供应链保障、利用数据 ...

Group 1: Company Operations - The company has successfully completed a 1.5 times expansion of its coenzyme Q10 raw material production line, with new fermentation tanks successfully tested and currently maintaining a strong production and sales momentum [2][3] - The price of Vitamin A has decreased due to market fluctuations, while DHA products have improved competitiveness through technological upgrades and market promotion, laying a solid foundation for future market expansion [2][3] - Other raw material products such as astaxanthin and Vitamin K2 are showing significant positive trends [3] Group 2: Market Expansion and Product Development - The company's health food finished product business is expanding well in the domestic market, benefiting from the rapid development of the domestic health consumption industry [3] - The overseas subsidiary VitaBest's soft capsule production line is under construction and is expected to be operational in the second half of the year; Zipfizz functional beverages will introduce four new flavors and a new "YOU" ready-to-drink product series [3] Group 3: Regulatory and Market Challenges - The current tariff rate for coenzyme Q10, Vitamin A, Vitamin D3, and Vitamin K2 exported to the U.S. is 20%. The company has mitigated the tariff impact by raising sales prices or having downstream customers bear the tariff costs; the sales proportion of vitamin products in the U.S. is small, limiting the overall impact [3] Group 4: Marketing Strategies - The company plans to develop marketing strategies for end-nutrition health products based on industry characteristics, market demand, brand positioning, and resource integration capabilities, utilizing market insights and data-driven approaches to create market-leading products [3] Group 5: Synthetic Biology Applications - The company employs synthetic biology as a foundational technology for the large-scale production of various raw material products, including coenzyme Q10, NMN, NADH, Vitamin K2, nattokinase, PQQ, SAMe, DHA, and ARA, while also exploring new products such as astaxanthin, algal oil EPA, glutathione, inositol, calcium pantothenate, and biological sweeteners [3]

Core Viewpoint - The company reported strong financial performance in 2024 and Q1 2025, driven by increased sales of Coenzyme Q10 and a rebound in Vitamin A market prices, indicating a positive growth trajectory in the health supplement sector [1][4]. Financial Performance - In 2024, the company achieved revenue of 3.24 billion yuan (up 4.43% year-on-year), with a net profit attributable to shareholders of 342 million yuan (up 23.59% year-on-year) and a non-recurring net profit of 339 million yuan (up 20.80% year-on-year) [1]. - For Q1 2025, the company reported revenue of 827 million yuan (up 11.31% year-on-year), a net profit of 122 million yuan (up 71.97% year-on-year), and a non-recurring net profit of 119 million yuan (up 70.03% year-on-year) [1][4]. Product Performance - Revenue breakdown for 2024 shows that health supplements, Coenzyme Q10 series, Vitamin A series, and other products generated revenues of 1.964 billion, 726 million, 273 million, and 277 million yuan respectively, with year-on-year growth rates of +3.67%, -1.11%, +27.17%, and +6.87% [1]. - Gross profit contributions from product lines were 55.47% for health supplements, 28.02% for Coenzyme Q10, 7.17% for Vitamin A, and 9.33% for other products, with Vitamin A's gross margin increasing significantly by 36.74 percentage points [2]. Capacity Expansion and Globalization - The company is actively expanding production capacity, with Coenzyme Q10 production lines operating at full capacity and a 1.5 times expansion project completed, increasing annual capacity to 920 tons [3]. - The company has successfully acquired Activ Nutritional, LLC, enhancing its global presence and brand portfolio, while also launching new functional beverage products [3]. Cost Management and Efficiency - In Q1 2025, the company achieved a gross margin of 41.74% and a net profit margin of 14.72%, with significant improvements in management expense ratios [4]. - The company is focusing on optimizing supply chains and reducing costs through better governance of its overseas subsidiary, VitaBest [4]. Technological Advancements - The company is leveraging synthetic biology for the large-scale production of raw materials, achieving lower costs for Coenzyme Q10 and obtaining patents for high-yield production methods [5]. - The company aims to continue developing high-potential products using core technologies such as synthetic biology and microbial fermentation [5]. Investment Outlook - The company is positioned as a leader in the Coenzyme Q10 market with a market share of approximately 50% as of March 2025, and is expected to achieve revenues of 3.672 billion, 4.13 billion, and 4.563 billion yuan from 2025 to 2027, with corresponding net profits of 448 million, 540 million, and 629 million yuan [6].

Summary of Key Points Core Viewpoint - As of May 16, the total market financing balance decreased to 1.79 trillion yuan, indicating a slight reduction in investor activity in the market [1]. Company and Industry Analysis - The financing balance in the Shanghai market was 907.43 billion yuan, down by 0.92 billion yuan, while the Shenzhen market's balance was 882.06 billion yuan, also down by 0.92 billion yuan. The North Exchange's financing balance decreased to 5.38 billion yuan, down by 0.038 billion yuan [1]. - On May 16, a total of 1,712 stocks received net financing purchases, with 257 stocks having net purchases exceeding 10 million yuan. Notably, 22 stocks had net purchases over 50 million yuan [1]. - The top three stocks by net financing purchases on May 16 were: - China Merchants Bank: 170.42 million yuan - Tonghua Golden Horse: 167.08 million yuan - China Ping An: 136.61 million yuan [2]. - The industries with the highest concentration of stocks receiving net financing purchases over 50 million yuan included automotive, basic chemicals, and food and beverage, each with three stocks listed [1]. - The average ratio of financing balance to circulating market value for stocks with significant net purchases was 4.01%, with Dongtu Technology having the highest ratio at 9.79% [2]. - The financing net purchase rankings on May 16 highlighted several stocks, including: - Dongtu Technology: 8.04 million yuan, 7.58% increase - Tonghua Golden Horse: 16.71 million yuan, 2.45% increase - BYD: 9.85 million yuan, 3.28% increase [2][3].

每经记者｜赵李南 每经编辑｜魏官红 "从2011年上市到现在，对于市值管理，说实在话，我的初心很简单，把企业做好，扎扎实实做好。你有好的产品、好的市场，获得好的利润回报，回报股 东、回报社会、回报员工，我认为（这就是）最好的市值管理。"金达威董事长江斌说道。 2024年和今年一季度，金达威（002626.SZ，股价19.18元，市值116.99亿元）分别实现归母净利润约3.4亿元和1.2亿元，同比增长约23.6%和72%。 江斌解释称，一季度之所以能够取得这样的业绩，最主要的因素源于企业规模效应及管理效率的提升。 2025年一季度，金达威的整体销售毛利率约41.7%。2024年，金达威的维生素A、辅酶Q10和营养保健品的毛利率分别达到了32.8%、48.2%和35.2%。 "传统的鱼油市场本身已达百万吨级规模，但通过微藻生物制造的藻油（EPA/DHA）Omega-3，成本有望比鱼油（EPA/DHA）Omega-3更低，这个市场容量 非常巨大，以百万吨级来计。藻油有几个优势，一是可再生，只需要有钱投发酵罐；二是通过微藻异养无溶剂提纯，属植物源性产品，避免了海鲜过敏问 题；三是绿色环保，不涉及海洋资源过度捕捞和重 ...

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

证券代码：002626 证券简称：金达威 公告编号：2025-043 厦门金达威集团股份有限公司关于 公司董事会完成换届选举并聘任高级管理人员及其他人员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 其中宗耕先生为第九届董事会提名委员会主任。 一、第九届董事会成员情况 非独立董事：江斌先生（董事长）、顾卫华先生（副董事长）、陈佳良先 生、洪航先生、徐肖特先生、吴轶先生（职工代表董事） 独立董事：王大宏先生、王肖健先生、宗耕先生 公司董事会中兼任高级管理人员以及由职工代表担任的董事人数总计未超 过公司董事总数的二分之一；独立董事占董事会成员的比例不低于三分之一， 且任职资格和独立性已经深圳证券交易所备案审核无异议。公司第九届董事会 任期自 2025 年第一次临时股东大会审议通过之日起三年。 二、第九届董事会各专门委员会委员情况 公司第九届董事会下设四个专门委员会：战略委员会、提名委员会、薪酬与 考核委员会、审计委员会，具体情况为： 员，其中江斌先生为第九届董事会战略委员会主任。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 5 月 15 ...

邮箱：jie.lin@kingdomway.com 地址：福建省厦门市海沧新阳工业区阳光西路 299 号 特此公告。 证券代码：002626 证券简称：金达威 公告编号：2025-044 厦门金达威集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"公司"）于 2025 年 5 月 15 日召 开第九届董事会第一次会议，审议通过《关于聘任公司证券事务代表的议案》， 同意聘任林洁女士为证券事务代表（简历附后）。林洁女士已取得深圳证券交易 所颁发的《上市公司董事会秘书培训证明》，具备担任证券事务代表所需的专业 知识和履职能力，符合《中华人民共和国公司法》《深圳证券交易所股票上市规 则》等相关法律法规和规范性文件的规定。 林洁女士的联系方式如下： 电话：0592-3781888 厦门金达威集团股份有限公司 董 事 会 二〇二五年五月十五日 附件：林洁女士简历 林洁女士：1997 年 12 月出生，中国国籍，本科学历。2022 年 6 月至今就职 于厦门金达威集团股份有限公司证券事务部，已取得深圳证券交易所颁发的《上 ...